Company Description
SeqLL Inc. operates as a life sciences instrumentation and research services company.
It focuses on development of scientific assets and novel intellectual property across multiple omics fields.
The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data.
It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies.
In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies.
The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
| Country | NJ |
| Founded | 2014 |
| IPO Date | Aug 27, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 7 |
Contact Details
Address: 270 Sylvan Avenue, Suite 2230 Englewood Cliffs, New Jersey 07632 United States | |
| Phone | 2018994470 |
Stock Details
| Ticker Symbol | ATLN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001605888 |
| Employer ID | 46-5319744 |
| SIC Code | 7363 |
Key Executives
| Name | Position |
|---|---|
| Daniel Robert Jones | Co-Founder, President, Chief Executive Officer and Chairman |
| Frances P. Scally | Chief Financial Officer and Secretary |
| Erik Volke | Director of Operations |
| Brian Paras | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 28, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 28, 2024 | RW | Filing |
| Jun 27, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 17, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 9, 2024 | EFFECT | Notice of Effectiveness |